Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies

Rubinstein, Ethan; Corey, G. Ralph; Boucher, H; Niederman,; Shorr, Andrew F.; Torres, Antoni; Barriere, SL; Friedland, H. David

doi:10.1186/cc7474

Cited by 6 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, telavancin cure rates were significantly higher ( ) than that for vancomycin in patients P p .03 with pneumonia caused by S. aureus with a vancomycin MIC у1 mg/mL. Among the microbiologically evaluable patients who were infected with MRSA alone, treatment with telavancin resulted in numerically higher cure rates of 82%, compared with 74% for vancomycin, but this difference did not reach statistical significance [38].…”

Section: Clinical Experiencementioning

confidence: 49%

“…To examine telavancin's efficacy in the treatment of pneumonia, the results from the 2 protocols (ATTAIN 1 and 2) were combined [38]. When combining both studies, a total of 1503 patients were randomized and 658 (312 telavancin and 346 vancomycin) were clinically evaluable at the test-of-cure followup, defined as 14 days after receipt of the last dose.…”

Section: Clinical Experiencementioning

confidence: 99%

“…Telavancin has been studied in the treatment of complicated skin and skin-structure infections (ATLAS 1 and 2 trials) and hospital-acquired pneumonia (ATTAIN 1 and 2 trials) [37,38] in 4 double-blinded phase 3 studies. In each study, telavancin was administered in a dosage of 10 mg/kg per 24 h period and compared with vancomycin at 1 g every 12 h. Sites were allowed to adjust vancomycin dosing for renal insufficiency according to their institutional guidelines.…”

Section: Clinical Experiencementioning

confidence: 99%

See 2 more Smart Citations

Telavancin: A Novel Lipoglycopeptide

2009

View full text Add to dashboard Cite

Telavancin, a derivative of vancomycin, is a lipoglycopeptide antibiotic that has been shown to be effective for the treatment of complicated skin and skin-structure infections. It has also been effective in the treatment of gram-positive pneumonia. This antibiotic has a dual mechanism of action by inhibiting peptidoglycan synthesis and causing membrane depolarization. Telavancin is consistently active against Staphylococcus aureus, including methicillin-resistant S. aureus, vancomycin-intermediate S. aureus, linezolid-resistant S. aureus, and daptomycin-nonsusceptible strains. The drug is usually administrated intravenously at 10 mg/kg every 24 h. Telavancin is excreted by the kidneys, and thus, dosage adjustments are required in cases of renal failure. Clinical trials have demonstrated non-inferiority, compared with vancomycin, in the treatment of complicated skin and skin-structure infections and pneumonia. Telavancin is associated with higher rates of renal events, altered taste, nausea, and vomiting but lesser rates of pruritus and infusion-related events, compared with vancomycin.

show abstract

Section: Clinical Experiencementioning

confidence: 49%

Section: Clinical Experiencementioning

confidence: 99%

Section: Clinical Experiencementioning

confidence: 99%

See 1 more Smart Citation

Telavancin: A Novel Lipoglycopeptide

2009

View full text Add to dashboard Cite

show abstract

“…An extra analysis of data from ATTAIN 1 and 2 studies focused on efficacy of telavancin in treatment of HAP in severely ill and older patients [46]. The cure rate was evaluated at a test-of-cure visit scheduled 7 -14 days after the end of the study treatment.…”

Section: Hap Including Vapmentioning

confidence: 99%

“…Clinical cure rates, evaluated at a visit scheduled 7 -14 days after the last dose of medication, in the evaluable population of all the patients of ATTAIN study and in subpopulations of patients with ventilator-associated pneumonia and severely ill patients[44,46]. ALI: Acute lung injury; APACHE: Acute physiology and chronic health evaluation; ARDS: Acute respiratory distress syndrome; CPIS: Clinical pulmonary infection score.…”

mentioning

confidence: 99%

The role of telavancin in the treatment of MRSA infections in hospital

Bassetti

Mikulska

Righi

et al. 2009

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Background: Serious infections caused by Gram-positive bacteria, particularly multi-drug resistant, are an important cause of morbidity and mortality in patients admitted to intensive care units. Thus, new antibiotics covering these pathogens are urgently needed. Objective: To review characteristics of telavancin, a novel antibiotic intended to use for treating infections caused by difficult Gram-positive bacteria, such as Staphylococcus aureus, resistant to meticillin or vancomycin, multi-drug-resistant Streptococcus pneumoniae or glycopeptide-resistant enterococci. Methods: The studies on microbiological activity, clinical efficacy and safety of telavancin were reviewed. Results/conclusion: Telavancin is a lipoglycopeptide administered intravenously once-daily and excreted with urine. It proved to be microbiologically active against numerous Gram-positive pathogens including drug-resistant staphylococci, enterococci and pneumococci. Large randomized Phase II and III clinical trials on efficacy and safety of telavancin in treating complicated skin and skin structure infections reported telavancin to be non-inferior to standard treatment (mostly vancomycin). Preliminary data on telavancin in hospital-acquired pneumonia, including ventilator-associated pneumonia, documented that telavancin was efficacious for this indication. Overall incidence of adverse events was similar for telavancin and the comparator arms. Mild and transient disgeusia, nausea and vomiting resulted to be more frequent in telavancin group. Increase in creatinine values was also observed in telavancin arm. © 2009 Informa UK Ltd. All rights reserved

show abstract

Telavancin: A Review of Its Use in Patients with Nosocomial Pneumonia

Scott

2013

Drugs

View full text Add to dashboard Cite

Telavancin (Vibativ(®)), a lipoglycopeptide antibacterial agent, exhibits potent in vitro activity against Gram-positive bacteria associated with nosocomial pneumonia infections, including meticillin/oxacillin-resistant Staphylococcus aureus (MRSA) isolates and S. aureus isolates with reduced susceptibility to vancomycin. In two multinational trials in adult patients with nosocomial pneumonia caused by Gram-positive bacteria, including infections caused by MRSA isolates, a 1-h intravenous infusion of telavancin 10 mg/kg once daily was noninferior to intravenous vancomycin 1 g every 12 h in terms of clinical cure rates in the all-treated (AT) and clinically evaluable (CE) populations at the follow-up/test-of-cure (FU/TOC) visit. At this visit, clinical cure rates in the AT populations of both groups were approximately 60 %, with rates increasing to ≥80 % in the CE population. Pooled analyses of these trials also generally showed no significant between-group differences in clinical cure rates at the FU/TOC visit in the AT, CE and microbiologically evaluable (ME) populations. In the ME population, clinical cure rates were generally similar in the telavancin and vancomycin groups, irrespective of whether infections were mono- or polymicrobial, or caused by MRSA or methicillin/oxacillin-susceptible S. aureus isolates. Telavancin was generally well tolerated in patients with nosocomial pneumonia participating in clinical trials, with a tolerability profile that was generally similar to that of vancomycin. Telavancin offers an alternative treatment option in patients with nosocomial pneumonia caused by Gram-positive S. aureus, including those caused by MRSA and S. aureus isolates with reduced susceptibility to vancomycin.

show abstract

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies

Cited by 6 publications

References 0 publications

Telavancin: A Novel Lipoglycopeptide

Telavancin: A Novel Lipoglycopeptide

The role of telavancin in the treatment of MRSA infections in hospital

Telavancin: A Review of Its Use in Patients with Nosocomial Pneumonia

Contact Info

Product

Resources

About